Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Other Non Operating Income (2018 - 2025)

10x Genomics (TXG) has disclosed Other Non Operating Income for 8 consecutive years, with -$2.5 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income rose 16.56% to -$2.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, up 149.83% year-over-year, with the annual reading at $1.0 million for FY2025, 149.83% up from the prior year.
  • Other Non Operating Income hit -$2.5 million in Q4 2025 for 10x Genomics, down from -$1.2 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $4.0 million in Q4 2022 to a low of -$3.0 million in Q4 2024.
  • Historically, Other Non Operating Income has averaged -$116150.0 across 5 years, with a median of -$664000.0 in 2021.
  • Biggest five-year swings in Other Non Operating Income: tumbled 659.38% in 2021 and later skyrocketed 79800.0% in 2022.
  • Year by year, Other Non Operating Income stood at $5000.0 in 2021, then surged by 79800.0% to $4.0 million in 2022, then dropped by 0.33% to $4.0 million in 2023, then crashed by 176.57% to -$3.0 million in 2024, then grew by 16.56% to -$2.5 million in 2025.
  • Business Quant data shows Other Non Operating Income for TXG at -$2.5 million in Q4 2025, -$1.2 million in Q3 2025, and $2.6 million in Q2 2025.